Tariku Damte Ayalew, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 16000 Johnston Memorial Drive, Abingdon, VA 24211 Phone: 301-618-3772 Fax: 301-618-2986 |
Preetham Talari, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 16000 Johnston Memorial Dr Fl 4, Abingdon, VA 24211 Phone: 276-258-1000 |
Dr. Brian Kermit Stiltner, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 16000 Johnston Memorial Dr, Fourth Floor, Abingdon, VA 24211 Phone: 276-258-4050 Fax: 276-258-4056 |
Dr. Rakesh Patel, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 16000 Johnston Memorial Dr, Abingdon, VA 24211 Phone: 276-258-4455 Fax: 276-258-4445 |
Carl Chotas, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 16000 Johnston Memorial Dr Fl 4, Abingdon, VA 24211 Phone: 276-258-1000 |
News Archive
Anacor Pharmaceuticals announced today that the University of California San Francisco (UCSF) has been awarded $718,136 in funding from the National Institutes of Health (NIH) to discover and optimize novel oxaboroles as antimalarial drugs in collaboration with Anacor Pharmaceuticals. The NIH grant provides support for the period beginning September 30, 2011 and ending September 29, 2012.
Oxygen Biotherapeutics, Inc. today announced that the company has begun distribution for its newly formulated Dermacyte™ Oxygen Concentrate for the beauty and skin care market. The over-the-counter product is a scientifically designed perfluorocarbon concentrate to enhance oxygen delivery to skin.
The Microbicides Development Programme announced earlier today that its MDP 301 effectiveness trial, which was conducted among almost 9,400 women in four African countries, found no evidence that the PRO 2000 microbicide reduces the risk of HIV infection.
Genentech, Inc., a wholly owned member of the Roche Group, announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin® (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC).
› Verified 1 days ago